Justices Told Gilenya Generic Stay Bid Is A Weak Cash Grab
A generic-drug maker told the U.S. Supreme Court on Wednesday not to let Novartis keep its monopoly over the blockbuster multiple sclerosis drug Gilenya while appealing a patent invalidation, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article